Evaluation of the VE1 Antibody in Thyroid Cytology Using Ex Vivo Papillary Thyroid Carcinoma Specimens
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Recently, VE1, a monoclonal antibody against the BRAFV600E mutant protein, has been investigated in terms of its detection of the BRAFV600E mutation. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in thyroid cytology samples is rarely performed, and its diagnostic value in cytology has not been well established. In present study, we explored VE1 immunoexpression in cytology samples from ex vivo papillary thyroid carcinoma specimens in order to minimize limitations of low cellularity and sampling/targeting errors originated from thyroid fineneedle aspiration and compared our results with those obtained using the corresponding papillary thyroid carcinoma tissues. Methods: The VE1 antibody was evaluated in 21 cases of thyroid cytology obtained directly from ex vivo thyroid specimens. VE1 immunostaining was performed using liquid-based cytology, and the results were compared with those obtained using the corresponding tissues. Results: Of 21 cases, 19 classic papillary thyroid carcinomas had BRAFV600E mutations, whereas two follicular variants expressed wild-type BRAF. VE1 immunoexpression varied according to specimen type. In detection of the BRAFV600E mutation, VE1 immunostaining of the surgical specimen exhibited 100% sensitivity and 100% specificity, whereas VE1 immunostaining of the cytology specimen exhibited only 94.7% sensitivity and 0% specificity. Conclusions: Our data suggest that VE1 immunostaining of a cytology specimen is less specific than that of a surgical specimen for detection of the BRAFV600E mutation, and that VE1 immunostaining of a cytology specimen should be further evaluated and optimized for clinical use.
Abstract
Background: Recently, VE1, a monoclonal antibody against the BRAFV600E mutant protein, has been investigated in terms of its detection of the BRAFV600E mutation. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in thyroid cytology samples is rarely performed, and its diagnostic value in cytology has not been well established. In present study, we explored VE1 immunoexpression in cytology samples from ex vivo papillary thyroid carcinoma specimens in order to minimize limitations of low cellularity and sampling/targeting errors originated from thyroid fineneedle aspiration and compared our results with those obtained using the corresponding papillary thyroid carcinoma tissues. Methods: The VE1 antibody was evaluated in 21 cases of thyroid cytology obtained directly from ex vivo thyroid specimens. VE1 immunostaining was performed using liquid-based cytology, and the results were compared with those obtained using the corresponding tissues. Results: Of 21 cases, 19 classic papillary thyroid carcinomas had BRAFV600E mutations, whereas two follicular variants expressed wild-type BRAF. VE1 immunoexpression varied according to specimen type. In detection of the BRAFV600E mutation, VE1 immunostaining of the surgical specimen exhibited 100% sensitivity and 100% specificity, whereas VE1 immunostaining of the cytology specimen exhibited only 94.7% sensitivity and 0% specificity. Conclusions: Our data suggest that VE1 immunostaining of a cytology specimen is less specific than that of a surgical specimen for detection of the BRAFV600E mutation, and that VE1 immunostaining of a cytology specimen should be further evaluated and optimized for clinical use.
참고문헌 (20)
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Rajagopalan H, "Tumorigenesis: RAF", RAS oncogenes and mismatch-repair status, 2002, pp.418, 934~
- Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)
- Kim JH, "BRAF V600E mutation is a useful marker for differentiating Rathke’s cleft cyst with squamous metaplasia from papillary craniopharyngioma", J Neurooncol, 123, pp.189~191 (2015)
- Ascierto PA, "Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma", J Clin Oncol, 31, pp.3205~3211 (2013)
- Tiacci E, "BRAF mutations in hairycell leukemia", N Engl J Med, 364, pp.2305~2315 (2011)
- Lee ST, "Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area", J Clin Endocrinol Metab, 97, pp.2299~2306 (2012)
- Kim YH, "A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma", Hum Pathol, 45, pp.1483~1488 (2014)
- Ritterhouse LL, "BRAF V600E mutation-specific antibody:a review", Semin Diagn Pathol, 32, pp.400~408 (2015)
- Zagzag J, "Clinical utility of immunohistochemistry for the detection of the BRAF V600E mutation in papillary thyroid carcinoma", Surgery, 154, pp.1199~1204 (2013)
- Routhier CA, "Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas", Hum Pathol, 44, pp.2563~2570 (2013)
- Koperek O, "Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma", Am J Surg Pathol, 36, pp.844~850 (2012)
- Lee SR, "VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases", Am J Clin Pathol, 143, pp.437~444 (2015)
- Wobker SE, "Use of BRAF V600E immunocytochemistry on FNA direct smears of papillary thyroid carcinoma", Cancer Cytopathol, 123, pp.531~539 (2015)
- Rossi ED, "Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas:a cytohistologic institutional experience", Cancer Cytopathol, 122, pp.527~535 (2014)
- Zimmermann AK, "Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma", Cancer Cytopathol, 122, pp.48~58 (2014)
- Ghossein RA, "Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression", J Clin Endocrinol Metab, 98, pp.E1414~E1421 (2013)
- Kawahara A, "Fixation effect of SurePath preservative fluids using epidermal growth factor receptor mutationspecific antibodies for immunocytochemistry", Cancer Cytopathol, 122, pp.145~152 (2014)
- Dvorak K, "Immunohistochemistry with the anti-BRAF V600E (VE1) antibody:impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma", Pathology, 46, pp.509~517 (2014)
- Jones RT, "Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia", Mod Path, 28, pp.596~606 (2015)